

Title:

Complimentary vertebrate *Wac* models exhibit phenotypes relevant to DeSanto-Shinawi Syndrome

Kang-Han Lee ^{1,^}, April M Stafford ^{2,^}, Maria Pacheco-Vergara ³, Karol Cichewicz ^{4,5}, Cesar P Canales ^{4,5}, Nicolas Seban ^{4,5}, Melissa Corea ^{4,5}, Darlene Rahbarian ^{4,5}, Kelly E. Bonekamp ⁶, Grant R. Gillie ⁶, Dariangelly Pacheco Cruz ^{2,7}, Alyssa M Gill ², Hye-Eun Hwang ¹, Katie L Uhl ², Tara E Jager ⁸, Marwan Shinawi ⁹, Xiaopeng Li ², Andre Obenaus ¹⁰, Shane Crandall ^{6,7}, Juhee Jeong ³, Alex Nord ^{4,5}, Cheol-Hee Kim ^{1,#}, Daniel Vogt ^{2,7,#}.

Affiliations:

- 1) Department of Biology, Chungnam National University, Daejeon 34134, Korea
- 2) Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University, Grand Rapids, MI, 49503, USA.
- 3) Department of Molecular Pathology, New York University College of Dentistry, New York, NY 10010, USA.
- 4) Department of Psychiatry and Behavioral Sciences, University of California Davis, Davis 95618, USA.
- 5) Department of Neurobiology, Physiology and Behavior, University of California Davis, Davis 95618, USA.
- 6) Department of Physiology, Michigan State University, East Lansing, MI 48824, USA.
- 7) Neuroscience Program, Michigan State University, East Lansing, MI 48824, USA.
- 8) Corewell Health, Grand Rapids, MI, 49503, USA.
- 9) Division of Genetics and Genomic Medicine, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, 63110, USA.
- 10) Director, Preclinical and Translational Imaging Center, School of Medicine, University of California Irvine, Irvine, CA 92697, USA.

[^] Equal contribution

Correspondence

Cheol-Hee Kim: zebrakim@cnu.ac.kr

Daniel Vogt: vogtdan2@msu.edu

Abstract

Monogenic syndromes are associated with neurodevelopmental changes that result in cognitive impairments, neurobehavioral phenotypes including autism and seizures. Limited studies and resources are available to make meaningful headway into the underlying molecular mechanisms that result in these symptoms. One such example is DeSanto-Shinawi Syndrome (DESSH), a rare disorder caused by pathogenic variants in the *WAC* gene. Individuals with DESSH syndrome exhibit a recognizable craniofacial gestalt, developmental delay/intellectual disability, neurobehavioral symptoms that include autism, ADHD, behavioral difficulties and seizures. However, no thorough studies from a vertebrate model exist to understand how these changes occur. To overcome this, we developed both murine and zebrafish *Wac/wac* deletion mutants and studied whether their phenotypes recapitulate those described in individuals with DESSH syndrome. We first show that the two *Wac* models exhibit craniofacial and behavioral changes, reminiscent of abnormalities found in DESSH syndrome. In addition, each model revealed impacts to GABAergic neurons and further studies showed that the mouse mutants are susceptible to seizures, changes in brain volumes that are different between sexes and relevant behaviors. Finally, we uncovered transcriptional impacts of *Wac* loss of function in mice that will pave the way for future molecular studies into DESSH. These studies present two new animals that begin to uncover some biological underpinnings of DESSH syndrome and elucidate the biology of *Wac*.

Introduction

Pathogenic variants in the WW domain-containing adaptor with coiled coil, *Wac*, gene cause a neurodevelopmental disorder called DeSanto-Shinawi (DESSH) syndrome (aka WAC-related disorder) [1]. DESSH syndrome is characterized by a constellation of developmental delay/intellectual disability, cranio-facial dysmorphism, hypotonia, seizure, gastrointestinal problems (e.g., constipation and gastroesophageal reflux), and ophthalmological abnormalities (e.g., refractive errors and strabismus) [1]. In addition, individuals with DESSH syndrome exhibit arrays of neurobehavioral phenotypes including aggression, attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD) and anxiety [1–5]. *Wac* is a known autism risk gene due to the enrichment of pathogenic genetic variants in ASD cohorts [6]. However, little is known about the function of *WAC* in the brain and whether suitable vertebrate models could explore the underlying biology of DESSH syndromes.

The *Wac* gene encodes a protein with WW and coiled-coil domains, common protein/protein interaction domains. A recent study assessed the role of evolutionarily conserved protein domains in the human *WAC* protein that uncovered an amino terminal nuclear localization signal as well as a highly conserved disorganized region that contains several putative phosphorylation motifs that are mutated in humans with known *WAC* variants [7]. While the functional role of these domains and of *WAC* itself are still poorly understood in vertebrates, a multitude of roles for the *WAC* protein have been proposed, including positive regulation of mammalian target of rapamycin (mTOR) signaling, mitosis, transcription and autophagy [8–11], which were worked out in *drosophila* and immortalized cell lines. However, whether these roles are conserved in vertebrates and their relevance to human DESSH symptoms is still unknown.




Figure 1: Generation and validation of murine *Wac* and zebrafish *waca* mutants. (A) Floxed mouse *Wac* genetic locus and genotyping primers. Genotyping primers (magenta lines) reside external to the loxP sites (orange triangles) flanking exon 5 and nearby introns. (B) The recombined DNA band was Sanger-sequenced and results show the start codon (blue) and the novel stop codon introduced by the frameshift mutation resulting from Cre-mediated deletion of the locus used to generate the locus. (C) Example images of adult WT and *Wac* Het mice. (D) DNA gel of genotyping for WT and recombined (Het) *Wac* alleles. (E) *waca* KO zebrafish were generated by CRISPR/Cas9. KO target sites for sgRNAs are indicated by red arrowheads and predicted protein structures for KO mutations indicated below panel. (F) WT and *waca* KO zebrafish have grossly normal sizes but *waca* KO exhibited a shortened jaw (black triangle) at 5 dpf. (G) example *waca* genotyping results. Abbreviations: (aa) amino acid; (bp) base pair; (Chr) chromosome; (dpf) days post fertilization; (WT) wild type. Scale bars (C) = 1 cm and (F) = 200 μ m.

To better understand Wac's role in vertebrates, we generated two species-specific vertebrate deletion models to assess whether Wac depletion could recapitulate symptoms associated with DESSH syndrome. The rationale for choosing mouse and zebrafish models were: 1) Both are vertebrates; 2) Unique genetic approaches in each model; 3) Species-specific phenotypic screening advantages; 4) Finally, utilizing two distinct vertebrate models to study key brain phenotypes will be a powerful means to uncover the fundamental biology of DESSH syndrome in a manner that is likely to reveal novel neurological underpinnings.

Our models revealed some similarities in core DESSH symptoms, including craniofacial dysmorphism and relevant behaviors implicating decreased learning and social interaction. Both models also displayed decreased GABAergic markers but only mice had increased seizure susceptibility, revealing some differences as well. Finally, we took advantage of the mouse model, which more closely resembles humans, to probe further into potential unexplored phenotypes and molecular changes that could serve as future studies. These showed differences in brain volume using MRI, seizure susceptibility and novel RNA expression changes due to loss of *Wac*. We present the first vertebrate disease models for DESSH syndrome and present multiple shared and unique phenotypes that could begin to inform the underlying biological mechanisms of this condition.

Results

Validation of murine *Wac* and zebrafish *wac* mutants

We obtained sperm from the International Mouse Phenotyping Consortium (IMPC); the *Wac* murine locus on chromosome 18 was genetically modified to include flanking *loxP* (Flox) sites of exon 5 (Figure 1A). Sanger-sequencing of the genotyped PCR validated the locus and an introduced frameshift that resulted in a premature stop codon (Figure 1B). *Wac* *flox* founders were bred and crossed to *beta-actin-Cre* mice, which express *Cre* in germ cells [12]. We generated wild type (WT) and constitutive heterozygous (Het) progeny of similar size (Figure 1C) but not any live homozygous knockouts. Findings were consistent with data from the IMPC; constitutive *Wac* KOs are embryonic lethal. Results of genotyping using PCR are shown in Figure 1D.

Zebrafish harbor two *wac* loci on chromosome 12, *waca*, and 2, *wacb*, genes. A CRISPR/CAS9 approach was used to target these loci. The *waca* mutant had a deletion in coding exon five (Figure 1E) with *waca* progeny grossly normal in size by 5 days post fertilization (dpf) but with a shortened lower jaw (Figure 1F); genotyping results are shown in Figure 1G. However, since *wacb* zebrafish showed no overt phenotypes, *waca* and *wacb* double KOs could be only be obtained at a very low rate (data not shown) and the *waca* KOs show other phenotypic differences (see below) that *wacb* KOs lack, we chose to solely focus on *waca* KOs for this report.

Craniofacial changes in murine and zebrafish mutants




Figure 2: Craniofacial changes in mutants. (A, B) Dorsal views of the P0 calvaria stained with Alizarin red for bone. (A', B') The suture and fontanel areas in (A) and (B) are pseudo-colored green (anterior) and orange (posterior). (C, D) Dorsal views of P30 WT and *Wac* Het skull bones; arrow (D) points to a gap in the interfrontal suture. (E, F) Quantification of P0 fontanel suture areas pseudo colored in A' and B'; WT n = 4, Het n = 5. Quantification of the skull width across the frontal (G) and parietal (H) bones at P30 in WT and *Wac* Hets; WT n = 4, Het n = 4. (I, J) The *waca* KO zebrafish show a shortened jaw structure, compared to WT. Lines denote lower jaw length. (K) Quantification of lower jaw length, data expressed as the mean \pm SEM; n = 9 WT, 11 *wac* Het and 4 *waca* KO, **p < 0.01. (L, M) Cartilage staining of zebrafish using alcian blue, ventral view. (N) Measurements of the width of Meckel's cartilage in *waca* KO zebrafish at 13 dpf (red line); WT n=10, KO n = 8. Data are expressed as the mean \pm SEM. *p < 0.05 and ***p < 0.001. Scale bars (B') = 1 mm, (D) = 4 mm, (J, M) = 200 μ m.

bioRxiv preprint doi: <https://doi.org/10.1101/2024.05.26.595966>; this version posted August 28, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license.

Craniofacial dysmorphism is a cardinal feature in patients with DESSH syndrome [1–3, 5, 13–17], with larger frontal facial features being common, including larger foreheads. We first wondered whether a reduction in *Wac* dosage in mice could recapitulate this finding. Postnatal day (P)0 and P30 mouse skulls were examined. During neonatal ages, a widening of the fontanelles and sutures along the midline of the calvaria was noted (Figure 2A, B). While both the anterior and posterior regions of the calvaria were affected, the anterior region had the greater change (Figure 2A, B, E, F with pseudo-colored areas in 2A', B'; anterior $p = 0.0001$, posterior $p = 0.01$). By P30, there remained a noticeable gap in the interfrontal suture of the *Wac* Het. Concomitantly, the width of the skull across the frontal bones was significantly increased in *Wac* Hets, while the width across the parietal bones was normal (Figure 2C, D, G, H, $p = 0.002$ Frontal width). A feature that was notable was a shortened lower jaw in the *waca* KO zebrafish compared to WTs at 10 dpf (Figure 2I-K, $p = 0.006$), suggesting similar abnormalities in frontal craniofacial structures. In addition, the *waca* mutants also exhibited changes in other frontal craniofacial features, including an increased width spanning Meckel's cartilage at 13 dpf (Figure 2L-N, $p = 0.02$). The *waca* KO zebrafish survived into adulthood and continued to show morphological craniofacial defects of shortened lower jaw, sunken head and broad nasal tip at adult stage (data not shown). Thus, both models exhibit craniofacial changes relevant to DESSH syndrome.

Behavioral changes in *Wac/wac* mutants

Loss of *Wac* may impact social/cognitive behavior, as seen among individuals diagnosed with DESSH syndrome and as previous models exhibit intellectual challenges [3, 5, 14, 15, 17]. We noticed that Het mutant mice had normal ambulation in the open field and could perform tasks (Figure S2A). In a 3-chamber social test, WT mice spent more time with a novel mouse versus an object but *Wac* Hets showed less distinction between a mouse and object (Figure 3A, $p = 0.005$). *Wac* Hets also had significant impairments in the Y-maze that tests working memory [18, 19] (Figure 3b, $p = 0.047$). Anxiety (elevated plus maze) and spatial memory (radial arm water maze) were not grossly changed but cohorts of *Wac* Hets trended towards impairment in each test (Figure S1B, C).

We next tested zebrafish in a social cohesion assay; WT fish stayed in close contact while *waca* KOs were dispersed during the trial, see heatmap distribution of zebrafish in Figure 3C, D. While both male and female zebrafish *waca* KOs showed deficits in this assay, we report the sexes independently since WT males and females had significant differences in baseline social cohesion. Moreover, male zebrafish *waca* KOs had a greater change in social cohesion than females (Figure 3E, F, $p = 0.0007$ males, $p = 0.01$ females). In a novel tank assay to test hyperactivity, male *waca* KO fish moved greater distances, throughout the test compared to WTs (Figure 3G, $p = 0.005$), while there was no significant differences in females. Thus, while some differences exist in zebrafish locomotion/hyperactivity, both models share deficits in social interactions.

Elevated seizure susceptibility and depleted GABAergic markers in *Wac* heterozygous mice




Figure 3: Behavioral changes in mutants. (A) 6–8 week WT and *Wac* Het mice were tested in the 3-chamber social/novel object test, WT $n = 16$ and Het $n = 15$, and the Y-maze (B), $n = 13$ both groups, with *Wac* Hets showing deficits in each. (C, D) Example heat maps during the 17–19-minute timeframe of the social cohesion test in zebrafish; *waca* KO males and females were more dispersed (E, F), see methods for test details. (G, H) Distance moved was greater in male *waca* KOs in the novel tank assay, $n = 11$, both groups, compared to females, $n = 12$ (WT) and 11 (KOs). Data are expressed as the mean \pm SEM; * $p < 0.05$, ** $p < 0.01$ and *** $p < 0.001$.

The previous behavioral changes suggested that core neuron cell ratios might be altered, potentially through an imbalance in GABAergic/glutamatergic neurons that could impact this and other disorders [20, 21]. Moreover, epilepsy has been observed in individuals with DESSH syndrome [1, 3, 4, 15, 17], thus, we first tested if loss of *Wac* expression was sufficient to increase seizures in our mouse model. We assessed whether the GABA_A receptor antagonist, pentylenetetrazol (PTZ), could induce seizures in mice with *Wac* loss of function. The drug was administered intraperitoneal at a subthreshold dose (50mg PTZ per kilogram of mouse body weight) that rarely elicited a tonic-clonic seizure in WTs. We hypothesized that if loss of *Wac* promoted a shift favoring brain excitation/inhibition then *Wac* hets would exhibit more severe seizure behaviors by P30.

PTZ was administered and mice were observed for 20 minutes (Figure 4A); most mice fully recovered by 15 minutes and all WT mice did not exhibit any behavioral changes by twenty minutes post injection. Behaviors included freezing, motor twitches, loss of balance, seizures and hyperactivity, which are detailed in the methods. While PTZ led to subtle behavioral changes in WT mice but rarely elicited a seizure, *Wac* Hets exhibited elevated seizure behaviors, including hunched body posture, arching tail and forelimb clonus as well as succumbing to seizures (Figure 4B, $p < 0.0001$). Thus, loss of *Wac* leads to increased seizure susceptibility in mice, consistent with one of the comorbidities observed in ~40% of individuals with DESSH syndrome. In contrast, when zebrafish were tested for seizure susceptibility, the *waca* KO did not show any gross changes although both WTs and mutants responded to PTZ (data not shown), suggesting that this specific symptom was not conserved between the 2 vertebrate models.

Some GABAergic deficits in mouse and zebrafish *Wac/wac* mutants

While we only found a susceptibility to seizures in mice, an imbalance in excitatory and inhibitory cell populations may still exist in each model but with differential impacts on seizures and/or behaviors. One possibility is a decrease in GABAergic cortical interneuron (CIN) function, a diverse group of inhibitory neurons whose dysfunction has been implicated in other syndromes with epilepsy and/or autism [22–27]. To assess whether *Wac* may impact CIN populations, we assessed 3 broad groups of CINs; parvalbumin (PV)+ and somatostatin (SST)+, which label ~70% of GABAergic interneurons [28], and *prospero* homeobox 1 (PROX1) expressing, which labels the majority of caudal derived interneurons [29]. The cell density of SST and PROX1 CINs were normal, but there was ~18% decrease in PV+ CINs in the Het (Figure 4C-F, $p = 0.02$); example images of SST and PROX1 cells are shown in Figure S3. To probe whether PV expression is due to loss of cells or simply the expression of PV, we assessed for the CIN marker, LHX6, which is expressed in all PV+ CINs in the somatosensory cortex [27]. We found no decrease in LHX6 cell numbers (Figure 4C, 4G-I), suggesting this phenotype is likely due to impacts upon PV expression rather than loss of this group of interneurons.




Figure 4: Murine *Wac* depletion leads to elevated seizure susceptibility and loss of GABAergic markers. (A) Schema depicting the seizure induction by PTZ. Briefly, P30 mice were administered PTZ intraperitoneally and then assessed for the highest seizure severity score over the course of 20 minutes. The maximum seizure severity score over 20 minutes was quantified (B); n = 16 (WTs) and 22 (Hets). (C) Table of cortical interneuron cell counts in the somatosensory cortex at P30. (D-F) Immunofluorescent images of PV and cell density quantification in mice somatosensory cortex, n = 3, both groups. (G-I) Immunofluorescent images of LHX6 and cell density quantification in mice somatosensory cortex, n = 3, both groups. Data are expressed as the mean \pm SEM, *p < 0.05 and ****p < 0.0001. Scale bar = 100 μ m (H).

We also studied GABAergic markers in *waca* KO zebrafish. We first probed via *in situ* for the various parvalbumin transcripts in zebrafish but found no differences, including *pvalb6*, which is the only one expressed in the brain (data not shown). We next looked at the pan GABAergic gene, *gad1b*, in the forebrain and compared *gad1b* expression in WT and *waca* KOs. Notably, we uncovered a significant reduction in expression (Figure S2, $p < 0.0001$). These and previous data suggest that GABAergic neuron populations are impacted by mouse and zebrafish *Wac/waca* loss of function a potentially contribute to DESSH syndrome.

Normal numbers of major brain cell types and proteins in *Wac* mutant mice brains

Since many antibodies are not available for zebrafish, and mice are closer to humans in gene conservation, we chose to focus on our mouse model to next assess if any other major brain cell populations, signaling events (including post-translational modifications) or gross synaptic markers were altered by loss of *Wac*. Thus, we first performed cell density counts for different classes of neuronal cells in our mouse model that included oligodendrocytes, astrocytes and microglia in P30 somatosensory cortices (Figure 5A). The total number of neurons was assessed by labeling for NeuN, while oligodendrocytes, astrocytes and microglia were labeled with OLIG2, S100 β and IBA1, respectively; images of cell types are shown in Figure S3. No differences in these major cell types were observed between the genotypes in mice.

Next, we assessed mouse P30 somatosensory cortices for proteins changed in other *Wac* models or markers of brain synapses. As expected, WAC protein was reduced 64% in the Hets (Figure 5B, C, $p = 0.002$). Despite previous reports in other models [8, 10], we did not observe differences in mTOR activity or ubiquitination of histone 2B. Key pathways including Wnt/beta-catenin and synaptic markers, PSD95 (excitatory synapses) and Gephyrin/Gad65/67 (inhibitory synapses), were not altered (Figure 5B, C). For the MAPK signaling pathway, there was a decrease in active ERK1, 38% and ERK2, 33%, in the *Wac* Hets (Figure 5B, C, pERK1 $p = 0.01$, pERK2 $p = 0.02$), suggesting that while major cell types and proteins involved brain function are not altered, some signaling events may be candidates for future studies to understand WAC function. However, while many neuronal populations had normal cell numbers and other molecular readouts were not changed, they were not recapitulated in this study.

Normal pyramidal neuron lamination and electrophysiological properties in mouse *Wac* Hets

Our data thus far revealed altered GABAergic neuron marker expression but no changes in other generic neuron numbers, glia numbers or synaptic protein abundance. However, these observations could still be true while subtypes of excitatory neurons in distinct cortical lamina or their physiological/synaptic properties are yet altered. Thus, we also assessed glutamatergic neuron laminar markers in the somatosensory cortices of P30 mice. SATB2, CTIP2 and TBR1 were labeled and the proportion of expressing neurons assessed in layers 2/3/4, 5 and 6, however, there were no significant laminar changes in the Het (Figure S4A-I). We also examined the intrinsic membrane properties of layer 2/3 neurons in the primary somatosensory cortex of adult WT and Het mice. Overall, there were no gross differences in passive or active membrane properties between *Wac* Het and WT cells (Figure S4J, 4K and Table S1), suggesting excitatory cortical neurons in the mutants have normal physiological properties. We also assessed synaptic function by measuring spontaneous excitatory postsynaptic currents (EPSCs) in layer 2/3 neurons. We found no differences between WT and *Wac* Het excitatory neurons




Figure 5: Cell counts and biochemical assessment of key markers in P30 *Wac* WT and Het mice. (A) WT and *Wac* Het somatosensory cortices were counted for major cell classes, including markers of neurons and glia, $n = 3$ each group, parentheses indicate Standard error of the mean. (B) P30 somatosensory cortex tissue was probed via western blotting for WAC and proteins known to be altered in other models or of brain markers. (C) Quantification of protein bands were normalized to GAPDH or the total protein if a phosphorylated protein. Data are expressed as the mean \pm SEM, $n = 4$ all groups. * $p < 0.05$ and ** $p < 0.01$. Abbreviations: (WB) western blot and (kDa) kiloDaltons.

Next, we assessed mouse P30 somatosensory cortices for proteins changed in other *Wac* models or markers of brain synapses. As expected, WAC protein was reduced 64% in the Hets (Figure 5B, C, $p = 0.002$). Despite previous reports in other models [8, 10], we did not observe differences in mTOR activity or ubiquitination of histone 2B. Key pathways including Wnt/beta-catenin and synaptic markers, PSD95 (excitatory synapses) and Gephyrin/Gad65/67 (inhibitory synapses), were not altered (Figure 5B, C). For the MAPK signaling pathway, there was a decrease in active ERK1, 38% and ERK2, 33%, in the *Wac* Hets (Figure 5B, C, pERK1 $p = 0.01$, pERK2 $p = 0.02$), suggesting that while major cell types and proteins involved brain function are not altered, some signaling events may be candidates for future studies to understand WAC function. However, while many neuronal populations had normal cell numbers and other molecular readouts were not changed, they were not recapitulated in this study.

(Figure S4L, M), suggesting that local excitatory neurons in the neocortex are not measurably impacted by *Wac* depletion in the Het mice.

Increased brain volume in *Wac* Het mice with a male bias

While our zebrafish model is similar to the mouse in many core symptoms that presents in humans, the *Wac* Het mice recapitulate almost all DESSH syndromes yet tested. Thus, we wanted to take advantage of this model to understand if there may be more changes to the mouse Het brain that could underlie core and other symptoms relevant to humans. Since craniofacial symptoms exist in nearly all DESSH patients and our models have these same alterations, we hypothesized that alterations to the skull shape may also be correlated with altered brain volume. To determine what regions of the mutant mouse brains may be anatomically different, we performed magnetic resonance imaging (MRI) on P30 fixed WT and *Wac* Het brains of both sexes. We first assessed total brain volume of the WT and Hets and found that male *Wac* mutants exhibit a larger whole brain volume than WT males; there were no significant differences in female brain volumes (Figure 6A, $p = 0.04$). Next, we examined specific regional volumetric changes, starting with cortical domains. Several alterations were observed in both males and some in females, with most cortical regions showing an increase in volume compared to WTs. Notably, only males had increased retrosplenial cortices, while only females showed increases in parietal cortices (Figure 6A, B, retrosplenial cortex male Het vs male WT $p = 0.002$ and female WT vs. female Het $p = 0.01$).




Figure 6: MRI reveals increased brain volume in mouse *Wac* Het males. (A) There was a significant increase in whole brain volumes in HET compared to WT male mice. Female HET mice did not exhibit significant changes in brain volume relative to WT. Data are expressed as the mean \pm SEM; * $p < 0.05$. (B) %change between cortical regions were larger in most HET mice areas, with distinct regions different between sexes. (Bolded bars indicate significant differences $p < 0.05$, t-test).

We also examined limbic regions and white matter track volumes in WT and *Wac* Het mice. As before, male mice had significant increases in both limbic and white matter volumes compared to females. Specifically, hippocampal ventral CA3 and dorsal CA1 regions were increased in males but not females (Figure S5, ventral CA3 male WT vs. male Het $p = 0.0003$ and dorsal CA1 male WT vs. male Het $p = 0.04$). Male specific increased volume was also observed in white matter dorsal fornix and corpus callosum tracts (Figure S6, 7b, dorsal fornix male WT vs. male Het $p = 0.006$ and corpus callosum male WT vs. male Het $p = 0.01$). Unfortunately, no DESSH syndrome individuals have been MRI assessed to date. However, these observations may be potential predictors of phenotypes that may arise as those with DESSH syndrome age into adulthood and whether there could be sex differences in humans.

RNA sequencing of mouse forebrains reveals DESSH syndrome candidate transcripts


In a similar logic to our above tests, we chose to focus on the mouse model to assess potential RNA transcripts that are changed due to *Wac* loss of function since the mouse model may be more relevant to humans with DESSH. To discover potential molecular changes that could inform future mechanistic studies, we performed bulk RNA-seq at P2, an age when mice are undergoing critical developmental milestones, including neuronal migration, cell death, axon and dendrite outgrowth as well as beginning synaptogenesis. We sequenced 14 WT and 10 *Wac* Het sex-balanced forebrain samples (Table S2), to a median sequencing depth of 50 million paired-end reads per sample (Figure S7; Table S2). As expected, we found significant correlations between sample

sex and sequencing depth, and principal component analysis (PCA) dimensions. No outliers were detected in the PCA space (Figure S8A-C).

Differential expression (DE) analysis was performed using edgeR general linear model (GLM), complemented with SVA batch correction method [30]. Due to reduced sample size, sex-stratified DE was performed without model corrections at FDR < 0.1 , 7 and found genes significantly upregulated and downregulated, respectively; and 385 and 564 upregulated and downregulated genes at a more inclusive $P < 0.05$ threshold. The directionality of DE was skewed towards downregulation, which is consistent with *Wac* function in promoting transcription [8] (Figure 9A, B, Tables S3-5). While *Wac* gene expression was subtly upregulated in the mutants ($\log_{2}FC = 0.09$, $P = 0.01$, FDR = 0.5), coverage of floxed *Wac* exon 5 was reduced by 50% in Het samples (Figure S9), consistent with compensatory upregulation. Western blot found decreased WAC protein expression (Figure 5) and no evidence of mutant isoforms, demonstrating that mutant *Wac* transcript is unlikely to be stably translated.

Sex-stratified DE in females identified 3 genes passing FDR < 0.1 , 1 upregulated and 2 downregulated, and 0 DE genes in males. At $P < 0.05$, the number of DE genes was higher in males, with 303 upregulated and 275 downregulated, in contrast to 193 upregulated and 149 downregulated genes in females (data not shown). Sex-stratified transcriptomic signatures were directionally correlated with each other, indicating similarity and consistency of the signatures across sexes and replicates. (Figure S10). However, the higher number of genes passing $P < 0.05$ in males suggests a potential sex-bias of differential expression potentially similar to the greater changes in mouse MRI brain volumes in males.

RNF20/40/WAC complex plays an important role in regulating chromatin accessibility and transcription through H2B ubiquitination [8]. It also mediates transcription elongation, and indirectly, splicing [45]. We performed event-based differential splicing (DS) analysis using MAJIQ2.5 pipeline [46]. We found 13 DS junctions passing thresholds of 10% delta percent spliced in (dPSI) between WT and *Wac* Het, at 80% confidence level. As expected, we found two significant events representing floxed *Wac* exon skipping, and one intron retention in the *Cre* transgene locus *Gt(ROSA)26Sor*. We also detected skipped exons in *Snhg14*, alternative splice donors in *Dnmbp* and *Trmt61b*, alternative splicing acceptors in *Ssfp1* and *Trmt13*, retained introns in *Gm21992* and *Pigf*, and reduced intron retention in *Zc3h7a* (Figure S11, Table S7). None of these genes were identified as significantly differentially expressed. Alternative splicing of *Snhg14*, is of particular interest. It is an antisense transcript located in the *Ube3a* locus, a genomic region orthologous to human 15q11-13, which loss of function and imbalanced imprinting is responsible for neurodevelopmental disorders Prader-Willi and Angelman syndromes. Differential splicing of *Ssfp1*, which encodes a protein member of the chromatin transcription elongation complex FACT, suggests presence of a feedback mechanism regulating transcription elongation [47]. Overall, our data shed new light on the transcriptomic mechanisms and phenotypes of *Wac* haploinsufficiency and provide further context for the existing studies of DESSH syndrome.



Discussion

DESSH syndrome is a monogenic disorder that results in variable degrees of developmental delay/intellectual disability, craniofacial dysmorphic features, ophthalmological and gastrointestinal problems, hypotonia and other neurological changes that may underlie the elevated co-diagnoses of ASD, ADHD and seizures. Previous work identified distinct molecular and cellular changes, including alteration to the mTOR signaling pathway and nuclear regulation of transcription that may also overlap with our studies. A major limitation is that these previous studies were restricted to invertebrates and cell lines but not vertebrates. Thus, we sought to test if genetic depletion models of the *Wac* gene in vertebrates could recapitulate some of the reported symptoms in humans and further use our mouse model to probe novel anatomical and molecular changes for future studies. While the

mouse and zebrafish models mostly recapitulated most core DESSH symptoms tested herein they were not completely aligned. However, each provided a rich resource that could prove to be great tools in understanding the biological mechanisms underlying the syndrome as well as testing future therapeutics, which was further explored with our mouse model.

Craniofacial dysmorphism and social behavior deficits are highly prevalent in DESSH, with craniofacial dysmorphism existing in almost 100% of those diagnosed with DESSH while autism behaviors like those similar to the social deficits observed here are seen in roughly 40% of patients (Marwan Shinawi, unpublished results), which were recapitulated in both vertebrate models. Surprisingly, we found a robust sensitivity to a seizure inducing drug in mice but not zebrafish, suggesting some differences between models although a core phenotype in DESSH patients. Despite this difference, both models showed impacts upon GABAergic neuron marker expression. These changes in GABAergic neuron markers may or may not underlie the common behavioral social changes in each model while the seizures may have a different underlying mechanism. Ultimately, these data present two novel vertebrate DESSH models that could provide new insights into *Wac* loss of function and the impacts that this gene regulates upon brain function over an evolutionary timeline.

We and others have observed decreases of PV expression in other syndromic mouse models, including *Cntnap2* [24, 48, 49], suggesting this may be a common feature in some monogenic syndromes with overlapping phenotypic features. Individuals with DESSH syndrome have seizures [1, 3, 4, 15] and we found that subthreshold GABA receptor inhibition elicited seizures in *Wac* Het mice. The reaction to PTZ suggests that their brains are shifted towards increased excitability. It is also possible that this more excitable brain may influence the expression of PV, as we and others have found that brain activity can alter PV expression [26, 50]. Thus, it is still unclear whether the loss of PV leads to seizures in our model or if the elevated brain excitability could lead to changes in PV expression. No matter the cause, others have noted the importance of PV expression on behaviors relevant to ASD [51], suggesting that approaches to restore PV expression may be a future therapeutic to alleviate some symptoms of DESSH syndrome.

Some novel findings beyond phenotyping of our vertebrate models manifested that may be relevant for human symptoms. First, mutant male mice exhibit volumetric increases in several brain regions as adults, suggesting sex differences may arise in DESSH patients as they age and specific brain regions should be further explored. Zebrafish also have craniofacial extensions in the forebrain region.

Finally, our transcriptomic characterization of the *Wac* mouse model at P2 identified DE genes enriched in cell adhesion, neuron differentiation and cytokine production that may be future targets to understand underlying mechanisms. The magnitude of DE was stronger in males and highly concordant in females. Analyses identified 13 altered splicing events in 9 genes, including *snhg14*, an antisense transcript in the *Ube3a* locus, associated with Angelman and Prader-Willi syndromes, suggesting convergence of neurodevelopmental pathways. To determine which cell types are affected by *Wac* haploinsufficiency our DE and DS results need further validation at the single cell level, which will be done in future studies. Overall, our transcriptomic results support a role for *Wac* in neurodevelopment and regulation of transcription. We generated new vertebrate models to assess DESSH syndrome. These phenotypes are a first attempt at understanding this complex ultrarare disorder and offer tools to probe further biological mechanisms and therapeutics.

Materials and methods

Animals: Mouse model. We thank the Wellcome Trust Sanger Institute Mouse Genetics Project (Sanger MGP) and its funders for providing the conditional mutant mouse gamete (C57BL/6N-*Wac*^{tm2c(EUCOMM)Wtsi}/Wtsi). Funding information may be found at www.sanger.ac.uk/mouseportal, associated primary phenotypic information at www.mousephenotype.org and data about the development of these technologies [52–56]. Sperm harboring the *Wac* conditional allele was used to fertilize C57BL6/N donor eggs; progeny were then genotyped via polymerase chain reaction (PCR). We next bred *Beta actin-Cre* mice [12] with *Wac*^{Flx} mice to generate wild type (WT) and constitutive Het mice. After germline recombination, *Wac* Het mice were backcrossed and bred with CD-1 mice for at least three generations before being used for experiments, which were performed under the approval of Michigan State University's Campus Animal Resources. **Zebrafish model.** Zebrafish (*Danio rerio*) were maintained at 28.5°C with a 14 hours light/10 hours dark condition and fed three times a day. Zebrafish embryos were cultured in egg water (pH 7.4) and embryonic stages were determined by standard method [57]. All zebrafish experiments were approved by the Institutional

Animal Care and Use Committees (IACUC) of Chungnam National University (CNU-00866) and zebrafish reared by standard lab protocols. For all assessments, males and females were tested. If no differences were noted, the data were combined for analyses. If differences were noted than the data were separated and presented independently.

Generation of waca KO zebrafish: Zebrafish *waca* gene sequence was acquired from the NCBI database (*waca*: NM_199660.1). The primer for in vitro transcription of sgRNA was designed by 5' - TAATACGACTCACTATAGCTACTACAACTGCAGGACAGGTTTAGAGCTAGAA -3' for the *waca* target site. Primer contained 5' T7 promoter and 15 nucleotides at 3' complement to the universal primer. Template for *in vitro* transcription of the sgRNA to knock-out *waca* was produced by PCR with primer 5' - TAATACGACTCACTATAGGGAGGAAGGACTGGCACACGTTTAGAGCTAGAA -3' [58]. *In vitro* transcription was carried out using PCR products and MaxiScript T7 Kit (Ambion). Cas9 expression vector pT3TS-nCas9n (Addgene), linearized with XbaI (NEB) and purified via DNA extraction kit (ELPIS). Cas9 mRNA was synthesized using mMESSAGE mMACHINE T3 Kit (Ambion) and tailed poly (A) with *E. coli* Poly (A) Polymerase (NEB). sgRNA of *waca* was injected with Cas9 mRNAs into 1-cell stage embryos.

Behavior (mouse): 6-8 week aged mice of both sexes were tested; no differences were observed in any assay between sexes and data represent both groups. The persons performing the behaviors and analyses were blinded to the genotypes.

3-chamber social interaction: During habituation, test mice had 10 minutes in the center of a rectangular chamber divided into 3-chambers by plexiglass containing small holes to navigate. Side chambers contained empty holders, with small holes allowing snout contact. Following initial habituation, an unfamiliar sex- and age-matched mouse (habituated to round holders/cages previously) was put in one of the chambers randomly with doors of the lateral chambers closed and a novel object in the other. The test subject explored the apparatus for 10 minutes. Sniffing time was recorded using an overhead video camera and analyzed using ANY-Maze software. Time spent in each chamber and interaction with mouse/object was recorded.

Y-maze: Individual mice were placed at the end of one arm of a Y-maze and allowed to explore for five minutes while being filmed by an overhead camera. Entries into all arms were noted (four paws need to be inside the arm for a valid entry) and a spontaneous alternation is counted if an animal enters three different arms consecutively. % of spontaneous alternation were calculated according to following formula: [(number of alternations) / (total number of arm entries - 2)] × 100.

Behavior (zebrafish):

Novel tank assay: Novel tank assay was performed as previously described [59–61]. 3 month/older WT and *waca* KO sibling zebrafish were tested in the behavior tank (24 x 15 x 15 cm). The back and sides were covered with non-transparent white paper. Behavior tests were recorded for 20 minutes using a video camera (Sony, HDRCX190). All fish were returned to facility system tanks after completion of the behavioral tests. Recorded video files were analyzed using EthoVision XT7 software (Noldus).

Social cohesion test: Zebrafish group social cohesion was measured [59, 60]. During one session, 5 WT sibling or *waca* KO sibling zebrafish were placed in the behavior tank. Fish groups were recorded for 20 minutes using a video camera (Sony, HDRCX190). Videos were analyzed using 12 individual screenshots taken every 10 seconds for 3-5 minutes as early phase and 17-19 minutes as late phase. Distances between individual zebrafish in the group were measured using ImageJ for each screenshot and compiled.

Cranio-facial analyses: **Mouse model.** The skulls were stained with Alizarin red for bone as previously published [62]. Quantification of the suture and fontanel areas and the skull width was performed from photographs using ImageJ. **Zebrafish model.** Zebrafish cartilage was stained by Alcian Blue (Sigma) as previously described [63, 64]. Zebrafish larvae at 13dpf were fixed with 4% paraformaldehyde (PFA) overnight at 4°C and treated with bleaching solution (3% H₂O₂/0.5% KOH in distilled water) for 30 minutes, rinsed out with Phosphate buffered saline with 0.1% Tween 20 (PBST). Specimens were transferred to methanol to store at -20°. Zebrafish cartilage was stained by Alcian blue solution (0.1% Alcian blue with 70% EtOH) for 1 hour and then dehydrated in 70% EtOH. Specimens were rinsed 100% PBST and then transferred to 90% glycerol with 1% KOH to analyze on a dissecting microscope.

Genotyping: Mouse model. Primers to detect the recombinant allele of the *Wac* genetic locus: Forward 5'-AGCTATCGCTGCTGTTGGG-3' and Reverse 5'-CAAATCCCACAGTCCAATGC-3'. Thermocycling conditions were: 95°C 3 minutes, (95°C 30 seconds, 58°C 30 seconds, and 72°C 45 seconds for 35 cycles), 72°C 3 minutes. Sanger sequencing to validate the recombinant locus was performed by GeneWiz using the same primers on gel-purified PCR products. **Zebrafish model.** Primers to detect the alleles of *waca*: Forward 5'-ATTGAAACCGGCAGATGATT-3' and Reverse 5'-TCAGTGGGAGAAACCCAAAG-3'. Thermocycling conditions were: 95°C 5 minutes, (95°C 30 seconds, 60°C 40 seconds, and 72°C 20 seconds for 40 cycles), 72°C 7 minutes and 15°C 10 minutes. Primers to detect the genotypic alleles of *wacb*: Forward 5'-ATACCAGTCAAAGAGTCACTCAGCGAATGA-3' and Reverse 5'-CACGTTCACCGGCCCCGTGAGAGAGACCAC-3'.

Immuno-fluorescent staining: At P30, mice were transcardially perfused with phosphate-buffered saline (PBS), followed by 4% paraformaldehyde. The brains were then removed and postfixed in PFA for 30 minutes. Brains were transferred to 30% sucrose for cryoprotection overnight after fixation and then embedded in optimal cutting temperature compound before coronally sectioned at 25µm via cryostat. Sections were permeabilized in a wash of PBS with 0.3% Triton-X100, then blocked with the same solution containing 5% bovine serum albumin. Primary antibodies (details can be found in Supplementary Table 8) were applied overnight at 4°C, followed by 3 washes. Secondary antibodies (Alexa-conjugated 488 or 594 anti-rabbit or mouse, 1:300, Thermo-Fisher) were applied for 1-2 hours at room temperature, followed by 3 washes and cover slipped with Vectashield. Cell counts were performed using Image-J software from images that included all cortical layers.

MRI acquisition and analysis: High-resolution ex vivo MRI was conducted on 4% paraformaldehyde-fixed brains using a 9.4T Bruker Advance (Bruker Biospin, Billerica, MA, USA) with the following parameters: TR/TE 3397/10.6, 10 evenly spaced echoes 10ms apart, matrix 1.75 X 1.25 (91µm isotropic), and 30 slices 0.5mm thick. T2-weighted imaging (T2WI) and T2 relaxation maps were computed as we previously described [65]. T2WI scans were skull stripped (masking) using the segmentation tool from the ITK-SNAP software (version 3.8.0, RRID:SCR_002010) [66]. The T2WI mask was then used to generate a 3D reconstruction of the brain. T2WI parametric maps were generated and corrected for bias field inhomogeneities prior to registration. From T2WI data, brain and regional volumes and T2 relaxation times were obtained. The Australian Mouse Brain Mapping Consortium (AMBMC) atlas [67, 68] was utilized to extract 40 bilateral regions using non-linear registration to each subject's T2 images. Regional labels were applied using Advanced Normalization Tools (ANTs) and manually inspected for registration quality. Outliers were identified by calculating the interquartile range (IQR) for each region where 1.5IQR above the first quartile or below the third quartile were identified and excluded using Microsoft Excel.

Microscopy: Mouse fluorescent images were acquired using a Leica DM2000 microscope with a mounted monochrome DFC3000G camera. Fluorescent images were adjusted for brightness/contrast and merged using Image-J software. The skulls were photographed with Nikon SMZ1500 stereomicroscope and Nikon DSRi1 camera. Zebrafish images were acquired using Leica TL 5000 microscope with DFC 7000T camera.

PTZ induced seizure assessments: 1 gram of Pentylenetetrazole (PTZ) powder dissolved into 250 ml of PBS and injected intraperitoneally at 50 mg of PTZ per gram of mouse body weight. After injection, mice explored a clean cage for 20 minutes. Seizure severity was scored based on a modified Racine scale [69]: 1) Freezing or idle behavior; 2) Muscle twitches and/or rhythmic head nodding; 3) Tail arching over the mouse's backside accompanied by the mouse assuming a hunched posture; 4) Forelimb clonus; 5) Tonic-clonic seizures with a recovery to normal behavior; 6) Uncontrolled running/jumping/hyperactivity; 7) Full body extension of limbs; 8) Death.

RNA-Sequencing and bioinformatics analysis: Twenty-four mouse brains (14 WT and 10 *Wac* HETs; 7, 7 and 5, males, females, respectively) were collected at P2 following instant decapitation. Samples were snap frozen on dry ice and stored at -80C until RNA preparation. On the day of RNA isolation, left and right forebrain hemispheres were separated from the hindbrain and the total RNA was consistently isolated from the right forebrain hemisphere. Total RNA was obtained using Ambion RNAqueous Total RNA Isolation Kit (cat# AM1912) and assayed via Agilent RNA 6000 Nano Bioanalyzer Kit/instrument. Sample RIN scores ranged from 6.9 to 9.8, with a mean RIN score of 9.4.

Poly-A-enriched mRNA libraries were prepared at Novogene using Illumina reagents. Libraries were sequenced using Illumina NovaSeq 6000 S4 system, paired-end 150 (PE150) method. Reads were aligned to mouse genome (GRCm38/mm10) using STAR (version 2.5.4b) [70], and gene counts were produced using featureCounts (Liao et al., 2014). On average, 50 million paired-end reads (PE) aligned per sample, with a range of 32 to 84 million reads.

Data quality was assessed using FastQC. FastQC: A Quality Control Tool for High Throughput Sequence Data. Available online at: <http://www.bioinformatics.babraham.ac.uk/projects/fastqc/> and principal component analysis (PCA) was used to determine presence of sample outliers. All 24 samples were qualified for the analysis. Raw RNA-seq fastq files and a gene count matrix is available on GEO (GSE264597).

Bioinformatic analysis was performed using R programming language version 4.2.1. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/> and RStudio integrated development environment version 2023.06.0. RStudio: Integrated Development Environment for R. Posit Software, PBC, Boston, MA. URL <http://www.posit.co/>. Plots were generated using ggplot2 R package version 3.4.0, URL: <https://link.springer.com/book/10.1007/978-3-319-24277-4>. Heatmaps were generated using pheatmap R package 1.0.12. pheatmap: Pretty Heatmaps_. R package version 1.0.12, <https://CRAN.R-project.org/package=pheatmap>. The analysis scripts are available at: https://github.com/NordNeurogenomicsLab/Publications/tree/master/Lee_et.al._2024%2C_Complimentary_vertebrate_Wac_models_exhibit_phenotypes_relevant_to_DeSanto-Shinawi_Syndrome.

Differential expression (DE) analysis: For DE analysis we used edgeR R package (Robinson et al., 2010). Genes with a minimum of 1 counts per million (CPM) in at least six samples were included in the analysis. The first surrogate variable from the SVA-batch-correction method was used as a covariate in the edgeR GLM model [71]. For sex-stratified DE, we used a threshold of CPM > 1 in at least 3 samples, and no batch correction. Reads Per Kilobase per Million mapped reads (RPKM) were used for plotting summary heatmaps and expression data of individual genes.

Gene ontology enrichment analysis: To test for enrichment of GO terms we used the TopGO R package version 2.34.0 (Bioconductor). Mouse Gene Ontology (GO) data was downloaded from Bioconductor (org.Mm.eg.db). For the analysis presented here, we restricted our testing to GO Biological Process annotations and required a minimal node size of 20, and at least 2 significantly DE genes in a GO term. We used the internal 'weight01' testing framework and the Fisher exact test, a strategy recommended for gene set analysis that generally accounts for multiple testing comparisons. For GO BP analysis, we reported terms with p-value<0.05. For all enrichment analysis, the test set of DE genes was compared against the background set of genes expressed in our study based on minimum read-count cutoffs described above.

Analysis code is available at:

[https://urldefense.com/v3/_https://github.com/NordNeurogenomicsLab/Publications/tree/master/Lee_et.al._2024%2C_Complimentary_vertebrate_Wac_models_exhibit_phenotypes_relevant_to_DeSanto-Shinawi_Syndrome__;JQ!!HXCxUKcI0tNGmjep5OYi3Z-2ICpXdVi5iivlNrqffntUlxCwJDU1JgPyTtFTU7qg0XsXJuzFU4f_7M5FVXwiPayDnAJaasqO\\$](https://urldefense.com/v3/_https://github.com/NordNeurogenomicsLab/Publications/tree/master/Lee_et.al._2024%2C_Complimentary_vertebrate_Wac_models_exhibit_phenotypes_relevant_to_DeSanto-Shinawi_Syndrome__;JQ!!HXCxUKcI0tNGmjep5OYi3Z-2ICpXdVi5iivlNrqffntUlxCwJDU1JgPyTtFTU7qg0XsXJuzFU4f_7M5FVXwiPayDnAJaasqO$)

Western blots: P30 somatosensory cortices were dissected and frozen on dry ice. Next, they were lysed in RIPA buffer containing protease and phosphatase inhibitors and combined with Laemmli buffer containing 2-Mercaptoethanol and incubated at 95°C for 5 minutes to denature the proteins. Equal amounts of protein lysates were separated on 10% SDS-PAGE gels and then transferred to nitrocellulose membranes. The membranes were washed in Tris-buffered saline with Tween-20 (TBST) and then blocked for 1 hour in TBST containing 5% non-fat dry milk (blotto, sc-2324 SantaCruz biotechnology). Membranes were then incubated with primary antibodies overnight at 4°C, washed 3 times with TBST, incubated with secondary antibodies for 1 hour at room temperature and then washed 3 more times with TBST. Membranes were next incubated in ECL solution (BioRad Clarity substrate 1705061) for 5 minutes and chemiluminescent images obtained using a BioRad Chemidoc™ MP imaging system. Primary antibody details can be found in Supplementary Table 8, secondary HRP antibodies were used at 1:4000 (BioRad). Uncropped western blots are shown in Supplementary Figure 15.

Whole-mount *in situ* hybridization (WISH): WISH was performed using DIG-labeled antisense RNA probes for *gad1b*. RNA probes were synthesized using DIG-RNA labeling kit (Roche) [72]. Zebrafish larvae were fixed in

4% PFA in PBS overnight at 4°C then dehydrated with 100% Methanol. Larvae were rehydrated with 0.1% Diethyl pyrocarbonate with PBST (DEPC-PBST, Sigma Aldrich). Larvae were permeabilized with 10µg/ml proteinase K (Roche) according to developmental stage. Larvae were re-fixed for 15 minutes in 4% PFA, washed with DEPC-treated PBST, and pre-hybridized in HYB solution (50% formamide, 5X saline sodium citrate, 50µg/ml heparin, 500 µg/ml torula RNA, 46mM citric acid pH 6.0, 0.1% Tween20) for 1 hour at 70°C. Antisense DIG-labeled RNA probes were added in HYB solution and incubated for overnight at 70°C. Larvae were washed in a preheated mixture of 50% saline sodium citrate containing 0.1% Tween-20 and 50% hybridization solution at 70°C. Larvae were blocked and then incubated with 1/4000 concentration of anti-DIG Fab fragment conjugated with alkaline phosphatase (Roche) overnight at 4°C. Larvae were washed in PBST then incubated in staining solution including NBT/BCIP as alkaline phosphatase substrate in the dark until sufficient staining appeared. Larvae were mounted in 90% glycerol in PBST and were visualized via dissecting microscope.

Quantification and statistical analysis: Statistical analyses were performed using Prism version 7, a p value of < 0.05 was considered significant. For parametric measures of two groups, a two-tailed T-test was performed; parametric measures of three or more groups utilized a ONE-Way ANOVA with Tukey post-test. If different statistical analyses were used they are denoted in figure legends.

Acknowledgements

AMS, DV, KU, TEJ and XL were funded by the Michigan State University/Spectrum Health Corporation; We would like to thank DubDub and Harrison Levon-James Allen for critical insights and providing resources during this study; **MP-V and JJ** were funded by NIDCR R01 DE026798; **KU, TEJ and XL** were also funded by the Cystic Fibrosis Foundation LI19XX0, the Cystic Fibrosis Research Inc., R01 HL153165-01A1. **ASN** was funded by NIMH R01 MH120513. **C-H K** was supported by grants from the National Research Foundation of Korea (2018M3A9B8021980, 2020R1A5A8017671, and 2021R1A2C1008506).

Conflict of interests

The authors report that they have no conflict of interests.

References

1. DeSanto C, D'Aco K, Araujo GC, Shannon N, DDD Study, Vernon H, et al. WAC loss-of-function mutations cause a recognisable syndrome characterised by dysmorphic features, developmental delay and hypotonia and recapitulate 10p11.23 microdeletion syndrome. *J Med Genet.* 2015;52:754–761.
2. Vanegas S, Ramirez-Montaño D, Candelo E, Shinawi M, Pachajoa H. DeSanto-Shinawi Syndrome: First Case in South America. *Mol Syndromol.* 2018;9:154–158.
3. Leonardi E, Bellini M, Aspromonte MC, Polli R, Mercante A, Ciaccio C, et al. A Novel WAC Loss of Function Mutation in an Individual Presenting with Encephalopathy Related to Status Epilepticus during Sleep (ESES). *Genes.* 2020;11.
4. Alawadhi A, Morgan AT, Mucha BE, Scheffer IE, Myers KA. Self-limited focal epilepsy and childhood apraxia of speech with WAC pathogenic variants. *Eur J Paediatr Neurol EJPN Off J Eur Paediatr Neurol Soc.* 2021;30:25–28.
5. Morales JA, Valenzuela I, Cuscó I, Cogné B, Isidor B, Matalon DR, et al. Clinical and molecular characterization of five new individuals with WAC-related intellectual disability: Evidence of pathogenicity for a novel splicing variant. *Am J Med Genet A.* 2022. 12 January 2022. <https://doi.org/10.1002/ajmg.a.62648>.
6. Iossifov I, O'Roak BJ, Sanders SJ, Ronemus M, Krumm N, Levy D, et al. The contribution of de novo coding mutations to autism spectrum disorder. *Nature.* 2014;515:216–221.

7. Rudolph HC, Stafford AM, Hwang H-E, Kim C-H, Prokop JW, Vogt D. Structure-Function of the Human WAC Protein in GABAergic Neurons: Towards an Understanding of Autosomal Dominant DeSanto-Shinawi Syndrome. *Biology*. 2023;12:589.
8. Zhang F, Yu X. WAC, a functional partner of RNF20/40, regulates histone H2B ubiquitination and gene transcription. *Mol Cell*. 2011;41:384–397.
9. McKnight NC, Jefferies HBJ, Alemu EA, Saunders RE, Howell M, Johansen T, et al. Genome-wide siRNA screen reveals amino acid starvation-induced autophagy requires SCOC and WAC. *EMBO J*. 2012;31:1931–1946.
10. David-Morrison G, Xu Z, Rui Y-N, Charng W-L, Jaiswal M, Yamamoto S, et al. WAC Regulates mTOR Activity by Acting as an Adaptor for the TTT and Pontin/Reptin Complexes. *Dev Cell*. 2016;36:139–151.
11. Qi F, Chen Q, Chen H, Yan H, Chen B, Xiang X, et al. WAC Promotes Polo-like Kinase 1 Activation for Timely Mitotic Entry. *Cell Rep*. 2018;24:546–556.
12. Lewandoski M, Meyers EN, Martin GR. Analysis of Fgf8 gene function in vertebrate development. *Cold Spring Harb Symp Quant Biol*. 1997;62:159–168.
13. Ho S, Luk H-M, Lo IFM. Extending the phenotype of DeSanto-Shinawi syndrome: A case report and literature review. *Am J Med Genet A*. 2021. 19 November 2021. <https://doi.org/10.1002/ajmg.a.62571>.
14. Uehara T, Ishige T, Hattori S, Yoshihashi H, Funato M, Yamaguchi Y, et al. Three patients with DeSanto-Shinawi syndrome: Further phenotypic delineation. *Am J Med Genet A*. 2018;176:1335–1340.
15. Lugtenberg D, Reijnders MRF, Fenckova M, Bijlsma EK, Bernier R, van Bon BWM, et al. De novo loss-of-function mutations in WAC cause a recognizable intellectual disability syndrome and learning deficits in *Drosophila*. *Eur J Hum Genet EJHG*. 2016;24:1145–1153.
16. Hamdan FF, Srour M, Capo-Chichi J-M, Daoud H, Nassif C, Patry L, et al. De novo mutations in moderate or severe intellectual disability. *PLoS Genet*. 2014;10:e1004772.
17. Alsahlawi Z, Jailani M, Alaradi H, AlAbbad A. A Case of DeSanto-Shinawi Syndrome in Bahrain with a Novel Mutation. *Case Rep Pediatr*. 2020;2020:8820966.
18. Kraeuter A-K, Guest PC, Sarnyai Z. The Y-Maze for Assessment of Spatial Working and Reference Memory in Mice. *Methods Mol Biol Clifton NJ*. 2019;1916:105–111.
19. Lalonde R. The neurobiological basis of spontaneous alternation. *Neurosci Biobehav Rev*. 2002;26:91–104.
20. Rubenstein JLR, Merzenich MM. Model of autism: increased ratio of excitation/inhibition in key neural systems. *Genes Brain Behav*. 2003;2:255–267.
21. Sohal VS, Rubenstein JLR. Excitation-inhibition balance as a framework for investigating mechanisms in neuropsychiatric disorders. *Mol Psychiatry*. 2019. 14 May 2019. <https://doi.org/10.1038/s41380-019-0426-0>.
22. Vogt D, Hunt RF, Mandal S, Sandberg M, Silberberg SN, Nagasawa T, et al. Lhx6 directly regulates Arx and CXCR7 to determine cortical interneuron fate and laminar position. *Neuron*. 2014;82:350–364.
23. Vogt D, Cho KKA, Lee AT, Sohal VS, Rubenstein JLR. The parvalbumin/somatostatin ratio is increased in Pten mutant mice and by human PTEN ASD alleles. *Cell Rep*. 2015;11:944–956.
24. Vogt D, Cho KKA, Shelton SM, Paul A, Huang ZJ, Sohal VS, et al. Mouse Cntnap2 and Human CNTNAP2 ASD Alleles Cell Autonomously Regulate PV+ Cortical Interneurons. *Cereb Cortex N Y N* 1991. 2018;28:3868–3879.
25. Kim YJ, Khoshkhoo S, Frankowski JC, Zhu B, Abbasi S, Lee S, et al. Chd2 Is Necessary for Neural Circuit Development and Long-Term Memory. *Neuron*. 2018;100:1180–1193.e6.
26. Malik R, Pai EL-L, Rubin AN, Stafford AM, Angara K, Minasi P, et al. Tsc1 represses parvalbumin expression and fast-spiking properties in somatostatin lineage cortical interneurons. *Nat Commun*. 2019;10:4994.
27. Angara K, Pai EL-L, Bilinovich SM, Stafford AM, Nguyen JT, Li KX, et al. Nf1 deletion results in depletion of the Lhx6 transcription factor and a specific loss of parvalbumin+ cortical interneurons. *Proc Natl Acad Sci U S A*. 2020. 2 March 2020. <https://doi.org/10.1073/pnas.1915458117>.
28. Wonders CP, Anderson SA. The origin and specification of cortical interneurons. *Nat Rev Neurosci*. 2006;7:687–696.
29. Rubin AN, Kessaris N. PROX1: a lineage tracer for cortical interneurons originating in the lateral/caudal ganglionic eminence and preoptic area. *PLoS One*. 2013;8:e77339.
30. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. *Bioinforma Oxf Engl*. 2012;28:882–883.

31. Choi J, Crotty S. Bcl6-Mediated Transcriptional Regulation of Follicular Helper T cells (TFH). *Trends Immunol.* 2021;42:336–349.
32. Bonnefont J, Tiberi L, van den Ameele J, Potier D, Gaber ZB, Lin X, et al. Cortical Neurogenesis Requires Bcl6-Mediated Transcriptional Repression of Multiple Self-Renewal-Promoting Extrinsic Pathways. *Neuron.* 2019;103:1096–1108.e4.
33. Tiberi L, Bonnefont J, van den Ameele J, Le Bon S-D, Herpoel A, Bilheu A, et al. A BCL6/BCOR/SIRT1 complex triggers neurogenesis and suppresses medulloblastoma by repressing Sonic Hedgehog signaling. *Cancer Cell.* 2014;26:797–812.
34. Wiegreffe C, Wahl T, Joos NS, Bonnefont J, Liu P, Britsch S. Developmental cell death of cortical projection neurons is controlled by a Bcl11a/Bcl6-dependent pathway. *EMBO Rep.* 2022;23:e54104.
35. Wu Q, Jia Z. Wiring the Brain by Clustered Protocadherin Neural Codes. *Neurosci Bull.* 2021;37:117–131.
36. Flaherty E, Maniatis T. The role of clustered protocadherins in neurodevelopment and neuropsychiatric diseases. *Curr Opin Genet Dev.* 2020;65:144–150.
37. Lefebvre JL. Neuronal territory formation by the atypical cadherins and clustered protocadherins. *Semin Cell Dev Biol.* 2017;69:111–121.
38. Tan X, Banerjee P, Guo H-F, Ireland S, Pankova D, Ahn Y-H, et al. Epithelial-to-mesenchymal transition drives a pro-metastatic Golgi compaction process through scaffolding protein PAQR11. *J Clin Invest.* 2017;127:117–131.
39. Phadnis VV, Snider J, Varadharajan V, Ramachandiran I, Deik AA, Lai ZW, et al. MMD collaborates with ACSL4 and MBOAT7 to promote polyunsaturated phosphatidylinositol remodeling and susceptibility to ferroptosis. *Cell Rep.* 2023;42:113023.
40. Lin Y, Huang M, Wang S, You X, Zhang L, Chen Y. PAQR11 modulates monocyte-to-macrophage differentiation and pathogenesis of rheumatoid arthritis. *Immunology.* 2021;163:60–73.
41. Yan F, Hu X, He L, Jiao K, Hao Y, Wang J. ADAM33 Silencing Inhibits Vascular Smooth Muscle Cell Migration and Regulates Cytokine Secretion in Airway Vascular Remodeling via the PI3K/AKT/mTOR Pathway. *Can Respir J.* 2022;2022:8437348.
42. Fujita M, Richards EM, Niciu MJ, Ionescu DF, Zoghbi SS, Hong J, et al. cAMP signaling in brain is decreased in unmedicated depressed patients and increased by treatment with a selective serotonin reuptake inhibitor. *Mol Psychiatry.* 2017;22:754–759.
43. Delhaye S, Bardoni B. Role of phosphodiesterases in the pathophysiology of neurodevelopmental disorders. *Mol Psychiatry.* 2021;26:4570–4582.
44. McGirr A, Lipina TV, Mun H-S, Georgiou J, Al-Amri AH, Ng E, et al. Specific Inhibition of Phosphodiesterase-4B Results in Anxiolysis and Facilitates Memory Acquisition. *Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol.* 2016;41:1080–1092.
45. Wu C, Cui Y, Liu X, Zhang F, Lu L-Y, Yu X. The RNF20/40 complex regulates p53-dependent gene transcription and mRNA splicing. *J Mol Cell Biol.* 2020;12:113–124.
46. Vaquero-Garcia J, Aicher JK, Jewell S, Gazzara MR, Radens CM, Jha A, et al. RNA splicing analysis using heterogeneous and large RNA-seq datasets. *Nat Commun.* 2023;14:1230.
47. Wright DE, Wang C-Y, Kao C-F. Flickin' the ubiquitin switch: the role of H2B ubiquitylation in development. *Epigenetics.* 2011;6:1165–1175.
48. Peñagarikano O, Abrahams BS, Herman EI, Winden KD, Gdalyahu A, Dong H, et al. Absence of CNTNAP2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. *Cell.* 2011;147:235–246.
49. Paterno R, Marafaga JR, Ramsay H, Li T, Salvati KA, Baraban SC. Hippocampal gamma and sharp-wave ripple oscillations are altered in a Cntnap2 mouse model of autism spectrum disorder. *Cell Rep.* 2021;37:109970.
50. Patz S, Grabert J, Gorba T, Wirth MJ, Wahle P. Parvalbumin expression in visual cortical interneurons depends on neuronal activity and TrkB ligands during an Early period of postnatal development. *Cereb Cortex N Y N 1991.* 2004;14:342–351.
51. Wöhr M, Orduz D, Gregory P, Moreno H, Khan U, Vörckel KJ, et al. Lack of parvalbumin in mice leads to behavioral deficits relevant to all human autism core symptoms and related neural morphofunctional abnormalities. *Transl Psychiatry.* 2015;5:e525.
52. Pettitt SJ, Liang Q, Rairdan XY, Moran JL, Prosser HM, Beier DR, et al. Agouti C57BL/6N embryonic stem cells for mouse genetic resources. *Nat Methods.* 2009;6:493–495.

53. Skarnes WC, Rosen B, West AP, Koutsourakis M, Bushell W, Iyer V, et al. A conditional knockout resource for the genome-wide study of mouse gene function. *Nature*. 2011;474:337–342.
54. Bradley A, Anastassiadis K, Ayadi A, Battey JF, Bell C, Birling M-C, et al. The mammalian gene function resource: the International Knockout Mouse Consortium. *Mamm Genome Off J Int Mamm Genome Soc*. 2012;23:580–586.
55. Ryder E, Gleeson D, Sethi D, Vyas S, Miklejewska E, Dalvi P, et al. Molecular characterization of mutant mouse strains generated from the EUCOMM/KOMP-CSD ES cell resource. *Mamm Genome Off J Int Mamm Genome Soc*. 2013;24:286–294.
56. White JK, Gerdin A-K, Karp NA, Ryder E, Buljan M, Bussell JN, et al. Genome-wide generation and systematic phenotyping of knockout mice reveals new roles for many genes. *Cell*. 2013;154:452–464.
57. Kimmel CB, Ballard WW, Kimmel SR, Ullmann B, Schilling TF. Stages of embryonic development of the zebrafish. *Dev Dyn Off Publ Am Assoc Anat*. 1995;203:253–310.
58. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science*. 2012;337:816–821.
59. Kim O-H, Cho H-J, Han E, Hong TI, Ariyasiri K, Choi J-H, et al. Zebrafish knockout of Down syndrome gene, DYRK1A, shows social impairments relevant to autism. *Mol Autism*. 2017;8:50.
60. Choi J-H, Jeong Y-M, Kim S, Lee B, Ariyasiri K, Kim H-T, et al. Targeted knockout of a chemokine-like gene increases anxiety and fear responses. *Proc Natl Acad Sci U S A*. 2018;115:E1041–E1050.
61. Park J-S, Choi T-I, Kim O-H, Hong TI, Kim W-K, Lee W-J, et al. Targeted knockout of duox causes defects in zebrafish growth, thyroid development, and social interaction. *J Genet Genomics Yi Chuan Xue Bao*. 2019;46:101–104.
62. Yen H-Y, Ting M-C, Maxson RE. Jagged1 functions downstream of Twist1 in the specification of the coronal suture and the formation of a boundary between osteogenic and non-osteogenic cells. *Dev Biol*. 2010;347:258–270.
63. Pruvot B, Curé Y, Djotsoa J, Voncken A, Muller M. Developmental defects in zebrafish for classification of EGF pathway inhibitors. *Toxicol Appl Pharmacol*. 2014;274:339–349.
64. Dalcq J, Pasque V, Ghaye A, Larbuisson A, Motte P, Martial JA, et al. RUNX3, EGR1 and SOX9B form a regulatory cascade required to modulate BMP-signaling during cranial cartilage development in zebrafish. *PLoS One*. 2012;7:e50140.
65. Jullienne A, Hamer M, Haddad E, Morita A, Gifford P, Hartman R, et al. Acute intranasal osteopontin treatment in male rats following TBI increases the number of activated microglia but does not alter lesion characteristics. *J Neurosci Res*. 2020;98:141–154.
66. Yushkevich PA, Piven J, Hazlett HC, Smith RG, Ho S, Gee JC, et al. User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. *NeuroImage*. 2006;31:1116–1128.
67. Ullmann JFP, Watson C, Janke AL, Kurniawan ND, Reutens DC. A segmentation protocol and MRI atlas of the C57BL/6J mouse neocortex. *NeuroImage*. 2013;78:196–203.
68. Richards K, Watson C, Buckley RF, Kurniawan ND, Yang Z, Keller MD, et al. Segmentation of the mouse hippocampal formation in magnetic resonance images. *NeuroImage*. 2011;58:732–740.
69. Vogt DL, Thomas D, Galvan V, Bredesen DE, Lamb BT, Pimplikar SW. Abnormal neuronal networks and seizure susceptibility in mice overexpressing the APP intracellular domain. *Neurobiol Aging*. 2011;32:1725–1729.
70. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. *Bioinforma Oxf Engl*. 2013;29:15–21.
71. Leek JT. Asymptotic conditional singular value decomposition for high-dimensional genomic data. *Biometrics*. 2011;67:344–352.
72. Thisse C, Thisse B. High-resolution *in situ* hybridization to whole-mount zebrafish embryos. *Nat Protoc*. 2008;3:59–69.